CARL — Carlsmed, Inc.

Carlsmed Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $16.1 million, a 58% increase year-over-year from $10.2 million in Q1 2025.
• Gross Margin: 77.1%, up from 74.9% in Q1 2025, attributed to efficiency improvements in production.
• Operating Expenses: $21.7 million, up from $13.4 million in Q1 2025, driven by increased R&D and sales/marketing expenses.
• Net Loss: $8.7 million, compared to a net loss of $5.7 million in Q1 2025.
• Adjusted EBITDA: Negative $7.5 million, worsening from negative $5.5 million in Q1 2025.
• Cash Position: $97.1 million as of March 31, 2026, with $15.6 million in outstanding debt.

2. Strategic Updates and Business Highlights

• Product Innovation: Continued focus on personalized surgery with the aprevo platform for lumbar and cervical spine fusion procedures.
• Surgeon Adoption: Surgeon user base grew by over 60% year-over-year, with strong engagement from early-career surgeons.
• Clinical Data: Published data shows a 74% reduction in surgery revision rates for patients using aprevo compared to traditional stock implants.
• Cervical Launch: First full quarter for the aprevo cervical fusion procedure, with over 20% of surgeon users trained on the new platform.
• Reimbursement Updates: Positive developments with CMS proposed rules for FY '27 that could simplify coding and increase reimbursement rates for aprevo procedures.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised full-year 2026 revenue expectations to between $72 million and $77 million, reflecting a 48% growth at the midpoint compared to 2025.
• Gross Margin Expectations: Anticipated to remain in the mid- to high 70s as the company scales and leverages efficiencies in production.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: The net loss and adjusted EBITDA have worsened compared to the previous year, indicating ongoing financial challenges.
• Operating Expenses Growth: Significant increase in operating expenses could pressure future profitability if revenue growth does not keep pace.
• Cervical Procedure ASP: The average selling price for cervical procedures is lower than lumbar, which may impact overall revenue per procedure as cervical becomes a larger portion of sales.

5. Notable Q&A Insights

• Surgeon Utilization: Strong enthusiasm and ongoing increase in utilization among newly onboarded surgeons, with a positive outlook for continued growth.
• Cervical Contribution: Expected to contribute high single-digit to low double-digit percentages to total revenue in 2026, with early traction noted.
• CMS Proposal Impact: The proposed CMS changes could simplify reimbursement processes and potentially increase procedure volumes, although it remains early to assess the full impact.
• Production Efficiency: Investments in digital production systems have led to a sustainable improvement in gross margins and operational efficiencies.

Overall, Carlsmed demonstrated strong revenue growth and strategic advancements in personalized surgery, although it faces challenges with increasing losses and operational expenses. The company remains optimistic about future growth driven by new product launches and favorable reimbursement developments.